NitroMed Plans Targeted BiDil Launch To Select Physicians; Sales Team Boasts Cardio Experience
This article was originally published in The Pink Sheet Daily
Executive Summary
BiDil launch targets physicians treating African-American heart failure patients over age 45. Sales force consists of reps with average 5.7 years cardiovascular sales experience.
You may also be interested in...
NitroMed Prices BiDil At $5-$10 Per Day Wholesale Acquisition Cost
The heart failure therapy, which is approved for use in self-identified black patients, will arrive in pharmacies the week of July 11 with a wholesale acquisition cost of $1.80 per tablet. NitroMed is planning a patient assistance program for uninsured patients.
NitroMed's BiDil Approved For Heart Failure In Self-Identified Black Patients
The hydralazine/isosorbide dinitrate combination is the first approval for a race-based indication. In its recent review of BiDil, an FDA advisory committee suggested race was serving as a surrogate for genomic markers. FDA suggests further study could expand BiDil's approval beyond self-identified black patients.
Purdue Signs On To Market Labopharm's Once-Daily Tramadol
Labopharm will receive up to $170 mil. under the licensing deal, including $20 mil. up front and $40 mil. upon NDA approval.